Botulinum toxin type A
Biologicalbotulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
Other names: BOTOX®, OnabotulinumtoxinA, BOTOX® Cosmetic, Vistabel®
NCT Number: NCT01608672
This is an observational study assessing patient satisfaction following at least 5 years of BOTOX® treatment for glabellar lines.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
South Yarra, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
Other names: BOTOX®, OnabotulinumtoxinA, BOTOX® Cosmetic, Vistabel®
Time frame: Study Day 1 (approximately 4-28 weeks following last treatment)
Participants assessed their overall satisfaction with their glabellar lines by answering FLSQ Question 5: "How satisfied are you with the effect your treatment had on your facial lines?" using a 5-point scale where: -2=very dissatisfied, -1=mostly dissatisfied, 0=neither dissatisfied nor satisfied, 1=mostly satisfied and 2=very satisfied. The percentage of participants mostly or very satisfied is reported.
Time frame: Study Day 1 (approximately 4-28 weeks following last treatment)
Participants rated their overall satisfaction with BOTOX® treatment by answering the question on the Patient Reported Overall Satisfaction of Effectiveness Questionnaire: "You have received BOTOX® facial aesthetic treatment(s) for at least 5 years. How satisfied overall are you with the effect of BOTOX®?" using the following possible answers: Very Dissatisfied, Mostly Dissatisfied, Neither Satisfied or Dissatisfied, Mostly Satisfied or Very Satisfied. The percentage of participants who answered Mostly Satisfied or Very Satisfied is reported.
Time frame: Study Day 1 (approximately 4-28 weeks following last treatment)
Physicians rated their overall satisfaction with BOTOX® treatment by answering the question on the Physician Reported Overall Satisfaction of Effectiveness Questionnaire: "You have treated this patient with BOTOX® facial aesthetic treatment(s) for at least 5 years. How satisfied overall are you with the effect of BOTOX®?" using the following possible answers: Very Dissatisfied, Mostly Dissatisfied, Neither Satisfied or Dissatisfied, Mostly Satisfied or Very Satisfied. The percentage of participants where the physician answered Mostly Satisfied or Very Satisfied is reported.
Allergan
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06308198
Glabellar Lines
Beijing, Beijing Municipality, China
View Trial DetailsNCT05496335
Glabellar Lines
Newport Beach, California, United States
View Trial DetailsNCT07622004
Glabellar Lines
Seoul, South Korea
View Trial DetailsNCT07398755
Glabellar Lines, Midface Volume Deficiency
Vienna, State of Vienna, Austria
View Trial Details